Iambic Therapeutics, Inc. - 10-Q Filing
Iambic Therapeutics reports Q3 2025 financial results featuring significant R&D and G&A expenditures alongside ongoing collaboration agreements with AbbVie, Bayer, Lundbeck, and Takeda.
Tickers: $IAM
Iambic Therapeutics reports Q3 2025 financial results featuring significant R&D and G&A expenditures alongside ongoing collaboration agreements with AbbVie, Bayer, Lundbeck, and Takeda.
Tickers: $IAM